Research

Open to Enrollment

DF/HCC 14-174: A Prospective, Longitudinal, Observational Study in Precursor Hematological Malignancies to Assess the Relationship between Molecular Events of Progression and Clinical Outcome

Participating Sites:

• Northern Light Cancer Care (Bangor, Maine)
• West Michigan Cancer Center (Kalamazoo, Michigan)
• Northside Hospital and Cancer Institute (Atlanta, Georgia)

DF/HCC 17-212: A Phase II Study of the CD38 Antibody Daratumumab in Patients with High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma (NCT 03236428)

Participating Sites:

• Pacific Cancer Care (Monterey Bay, California)
  
• Colorado Blood Cancer Institute (Denver, Colorado)

DF/HCC 17-718: A Phase I Study of Ipilimumab in Combination with Decitabine in Relapsed or Refractory Myelodysplastic Syndrome/Acute Myeloid Leukemia (NCT 02890329)

Participating Site:

• Blood and Marrow Transplant Group of Georgia at Northside Hospital (Atlanta, Georgia)

DF/HCC 18-370: Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE) (NCT 03689595)

Participating Site:

• Crowdfunding/Online Registration

DF/HCC 18-089: A Phase I/II Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma or Patients with Richter's Syndrome (NCT 03534323)

Participating Sites:

• Northern Light Cancer Care (Bangor, Maine)
• University of Iowa/Holden Cancer Center (Iowa City, Iowa)

Note: Refer to ClinicalTrials.gov for the full list of participating sites outside of the Blood Cancer Research Partnership.